TY  - RPRT
TI  - Adjuvant tislelizumab, lenvatinib, and capecitabine for resected biliary tract cancer: a prospective phase II trial.
AU  - Yun Feng
AU  - Ning Zhang
AU  - Yi-Ming Zhao
AU  - Qi Pan
AU  - An-Rong Mao
AU  - Wei-Ping Zhu
AU  - Ti Zhang
AU  - Lu Wang
PY  - 2026
DO  - 10.1186/s12916-026-04650-0
UR  - https://pubmed.ncbi.nlm.nih.gov/41578300/
ID  - 41578300
ER  -